Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308

Clinical Guidelines

Cochrane on Phytomedicines for Sickle Cell Disease , Cochrane; 2018 Feb 15; Oniyangi, Cohall, et al

New Choosing Wisely Guidance on BMT Released , Biol Blood Marrow Transplant; ePub 2018 Jan 19; Bhella, et al

Read more in Clinical Guidelines

Aggressive Lymphomas

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Read more in Aggressive Lymphomas

AML

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Read more in AML

ALL (Acute Lymphoblastic Leukemia)

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

ALL complications carry cognitive risks, Cheung YT et al. JAMA Pediatr. 2018 Sep 24. doi:10.1001/jamapediatrics.2018.2500.

Read more in ALL (Acute Lymphoblastic Leukemia)

Transfusion Medicine

Restrictive transfusion strategy in CV surgery doesn't raise long-term risk, Mazer CD et al. N Engl J Med. 2018 Aug 26. doi:10.1056/NEJMoa1808561

Diarrhea more severe in those with Type A blood, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Read more in Transfusion Medicine

Hodgkin Lymphoma

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

Read more in Hodgkin Lymphoma

Indolent Lymphoma

Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Read more in Indolent Lymphoma

Anemia

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Read more in Anemia

Cellular Therapy

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489

Read more in Cellular Therapy

Mantle Cell Lymphoma

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Read more in Mantle Cell Lymphoma

Mixed Topics

Low arginine linked to SFTS, Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Read more in Mixed Topics

Myelodysplastic Syndrome

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Read more in Myelodysplastic Syndrome

Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Read more in Bleeding Disorders

Practice Management

Oncology studies lack full disclosure of industry payments, Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

Read more in Practice Management